PRINCETON, N.J., July 8, 2026
UroGen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UGN-501, the company’s investigational next-generation oncolytic virus being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The regulatory clearance enables UroGen to initiate its planned Phase 1 clinical trial, with patient enrollment expected to begin during the fourth quarter of 2026. The study will evaluate the safety, tolerability, and feasibility of local intravesical administration of UGN-501 in patients with NMIBC. The milestone expands UroGen’s oncology pipeline and represents an important step toward developing a novel bladder-sparing therapeutic approach for patients who continue to face a high risk of disease recurrence despite currently available treatment options.
UGN-501 Designed to Destroy Tumor Cells and Activate Anti-Tumor Immunity
UGN-501 is a differentiated next-generation oncolytic virus engineered to selectively replicate within bladder tumor cells, resulting in direct tumor cell destruction while simultaneously stimulating an anti-tumor immune response. According to UroGen, the investigational therapy is supported by encouraging nonclinical data demonstrating cytotoxic activity across a broad panel of bladder cancer cell lines representing multiple disease stages and grades. Chief Medical Officer Mark Schoenberg, M.D., noted that patients with NMIBC continue to experience significant recurrence rates following existing therapies, highlighting the urgent need for innovative treatment options. He added that the FDA’s IND clearance allows the company to begin evaluating whether the promising preclinical profile of UGN-501 can translate into a safe and clinically meaningful treatment capable of improving outcomes for patients with recurrent bladder cancer.
Local Intravesical Delivery Aims to Address Significant Unmet Need
Unlike traditional systemic cancer therapies, UGN-501 is designed for local intravesical administration, delivering the investigational therapy directly into the bladder to maximize tumor exposure while potentially minimizing systemic toxicity. This localized treatment strategy aligns with UroGen’s broader mission of developing targeted therapies for urothelial cancers that preserve bladder function and reduce the need for invasive surgical interventions. The company believes that the unique mechanism of action of UGN-501, combining direct oncolysis with immune activation, may provide a differentiated therapeutic option for patients whose disease recurs after standard treatment. In addition to its initial focus on non-muscle invasive bladder cancer, UroGen also believes the underlying properties of the oncolytic virus platform could support future development across additional solid tumor indications, pending clinical and translational findings.
Advertisement
Clinical Development Strengthens UroGen’s Oncology Innovation Strategy
The advancement of UGN-501 further strengthens UroGen Pharma’s portfolio of innovative therapies for urothelial and specialty cancers. The company has previously developed its proprietary RTGel reverse-thermal hydrogel platform, which enables sustained local drug delivery within the urinary tract and has supported the development of non-surgical treatments for urothelial cancers. With the Phase 1 study scheduled to begin in Q4 2026, UroGen aims to generate the first clinical data evaluating the safety and feasibility of its next-generation oncolytic virus platform in bladder cancer. If successful, the program could expand therapeutic options for patients with NMIBC while also providing a foundation for broader applications of UGN-501 across multiple solid tumor indications, reinforcing the company’s long-term commitment to advancing innovative cancer therapies.
Source: UroGen Pharma press release
